Safety results from a phase 2 study of Palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Safety results from a phase 2 study of Palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer

【24h】

Safety results from a phase 2 study of Palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer

机译：安全结果来自帕尔巴昔米菌的第2期与Tamoxifen作为转移激素受体阳性乳腺癌的第一线治疗

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal 》 |2020年第2020期| 共4页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Safety results from a phase 2 study of Palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020 ,第期

机译：安全结果来自帕尔巴昔米菌的第2期与Tamoxifen作为转移激素受体阳性乳腺癌的第一线治疗
2. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3) [J] . Verma Sunil, Bartlett Cynthia Huang, Schnell Patrick, The oncologist . 2016 ,第10期

机译：激素受体阳性/ HER2阴性晚期转移性乳腺癌妇女中的Palbociclib与氟维西汀合用：来自多中心，随机，安慰剂对照的III期研究的详细安全性分析（PALOMA-3）
3. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3) [J] . Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, The oncologist . 2016 ,第10期

机译：激素受体阳性/ HER2阴性晚期转移性乳腺癌女性患者中Palbociclib与氟维西汀合用：来自多中心，随机，安慰剂对照的III期研究的详细安全性分析（PALOMA-3）
4. Study on the Efficacy Evaluation of Oral Sequential Tamoxifen in Postmenopausal Women with Hormone-dependent Breast Cancer [C] . Na Li, Yahua Sun, Sheng Zhao, International Conference on Life Sciences, Medicine, and Health . 2018

机译：激素依赖性乳腺癌后代妇女口腔序列儿毒素疗效评价研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter Randomized Placebo-Controlled Phase III Study (PALOMA-3) [O] . Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, 2016

机译：激素受体阳性/ HER2阴性晚期转移性乳腺癌妇女中的Palbociclib与氟维西汀合用：来自多中心随机安慰剂对照的III期研究的详细安全性分析（PALOMA-3）
7. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor‐Positive/HER2‐Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo‐Controlled, Phase III Study (PALOMA‐3) [O] . Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, 2016

机译：Palbociclib与激素受体阳性/ Her2阴性晚期转移性乳腺癌的女性联合妇女：来自多中心，随机，安慰剂控制，第三期研究的详细安全分析（Paloma-3）

Safety results from a phase 2 study of Palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer

著录项

相似文献

相关主题

期刊订阅